Measurement of sVEGF R1 and PlGF in Serum: Comparing Prototype Assays from Beckman Coulter, Inc. to R&D Systems Microplate Assays

REFERENCES

• Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83:37–45.
   PubMed Web of Science ®Google Scholar
• Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007; 197:211–214.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrin Metabol 2004; 89:770–775.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195:255–259.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF, Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190:1541–1547.
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30:151–159.
   PubMed Web of Science ®Google Scholar
• Teixeira PG, Cabral AC, Andrade SP, Reis ZS, da Cruz LP, Pereira JB, Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension. Hypertens Preg 2008; 27:65–73.
   PubMed Web of Science ®Google Scholar
• McKeeman GC, Ardill JES, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (VEGFR-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240–1246.
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555–5563.
   PubMed Web of Science ®Google Scholar
• Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and superimposed preeclampsia on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194:551–556.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk for preeclampsia. N Engl J Med 2004; 350:672–683.
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer HU, Augustin HG. Prospective analysis of placental growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hyperten Preg 2004; 23:101–111.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, A longitundinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Maternal-Fetal Neonatal Med 2008; 21:9–23.
   PubMed Web of Science ®Google Scholar
• Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet.Gynecol 2007; 196:239–236.
   PubMedGoogle Scholar
• Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim K. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197:28.e1–28.e1-6.
   Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308:1502–1504.
   Google Scholar
• Maynard SE, Moore Simas TA, Solitro MJ, Rajan A, Crawford S, Soderland P, Meyer B. Circulating angiogenic factors in singleton vs. multiple-gestation pregnancies. Am J Obstet Gynecol 2008; 200e1–200e7.
   Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6(4): 389–395.
   PubMed Web of Science ®Google Scholar
• Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188:177–182.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649–658.
   PubMed Web of Science ®Google Scholar
• Christinger HW, Fuh G, de Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. Biol Chem 2004; 279(11):10382–10388.
   Google Scholar
• Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Hyun Mee Ryu MH. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111:1403–1409.
   PubMed Web of Science ®Google Scholar